Abstract
p38α MAPK, a key therapeutic target in HNSCC can be considered as a prognostic marker and is implicated in response to radiation-therapy (RT). We compared the outcome of treatment viz. RT (group-I) and concurrent-RT (combination of RT with chemotherapy or surgery, group-II) with respect to p38α MAPK in HNSCC. The case-controlled study was performed on 143 HNSCC patients. From these p38α estimation was done thrice only for 104 patients (52 each in group-I and II), at pre, during and post-therapy periods using surface Plasmon resonance (SPR) technology, ELISA and western blot analysis. In HNSCC the over-expressed p38α levels declined after treatments in both the groups. The patients receiving only RT had a lower p38α level than those treated with concurrent-RT (p=0.009). Hence, p38α was found to be responsive to RT in HNSCC and it may be useful in predicting the treatment outcome and further improve the prognosis of disease in addition to clinical parameters.
Keywords: p38α, HNSCC, radiation therapy, chemotherapy, surgery.
Current Cancer Therapy Reviews
Title:Comparative Analysis of Current Modality of Therapy in Head and Neck Squamous Cell Carcinoma Correlating the Expression Level of p38α
Volume: 10 Issue: 3
Author(s): Kamaldeep Gill, Rahul Kumar, Abhishek Gupta, Bidhu Kalyan Mohanti and Sharmistha Dey
Affiliation:
Keywords: p38α, HNSCC, radiation therapy, chemotherapy, surgery.
Abstract: p38α MAPK, a key therapeutic target in HNSCC can be considered as a prognostic marker and is implicated in response to radiation-therapy (RT). We compared the outcome of treatment viz. RT (group-I) and concurrent-RT (combination of RT with chemotherapy or surgery, group-II) with respect to p38α MAPK in HNSCC. The case-controlled study was performed on 143 HNSCC patients. From these p38α estimation was done thrice only for 104 patients (52 each in group-I and II), at pre, during and post-therapy periods using surface Plasmon resonance (SPR) technology, ELISA and western blot analysis. In HNSCC the over-expressed p38α levels declined after treatments in both the groups. The patients receiving only RT had a lower p38α level than those treated with concurrent-RT (p=0.009). Hence, p38α was found to be responsive to RT in HNSCC and it may be useful in predicting the treatment outcome and further improve the prognosis of disease in addition to clinical parameters.
Export Options
About this article
Cite this article as:
Gill Kamaldeep, Kumar Rahul, Gupta Abhishek, Mohanti Kalyan Bidhu and Dey Sharmistha, Comparative Analysis of Current Modality of Therapy in Head and Neck Squamous Cell Carcinoma Correlating the Expression Level of p38α, Current Cancer Therapy Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/1573394710666141128001358
DOI https://dx.doi.org/10.2174/1573394710666141128001358 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Electrical Impedance Scanning - A New Diagnostic Tool in Cancer Detection: Current Status and Recent Developments
Current Medical Imaging Heterocyclic Curcumin Derivatives of Pharmacological Interest: Recent Progress
Current Topics in Medicinal Chemistry Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Integrins as Therapeutic Targets for Respiratory Diseases
Current Molecular Medicine The Anti-Tumor Mechanism and Target of Triptolide Based on Network Pharmacology and Molecular Docking
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA STAT 3 as a Target for Cancer Drug Discovery
Current Medicinal Chemistry Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?
Current Drug Targets ErbB Targeted Drugs and Angiogenesis
Current Vascular Pharmacology HSF1, A Versatile Factor in Tumorogenesis
Current Molecular Medicine Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Formulating SLN and NLC as Innovative Drug Delivery Systems for Non-Invasive Routes of Drug Administration
Current Medicinal Chemistry Occurrence, Functions and Biological Significance of Arginine-Rich Proteins
Current Protein & Peptide Science Drug Delivery and Cosmeceutical Applications of Poly- Lactic Acid Based Novel Constructs - A Review
Current Drug Metabolism Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments
Current Medicinal Chemistry - Anti-Cancer Agents Evaluation of Tissue and Serum Expression Levels of Lactate Dehydrogenase Isoenzymes in Patients with Head and Neck Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review
Current Drug Targets Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020)
Current Medicinal Chemistry Antiproliferative Activity of Cobra Venom Cytotoxins
Current Topics in Medicinal Chemistry